$TARS SEC Filings

The following unaudited pro forma condensed combined financial information combines the historical financial position and results of operations of Tarsus Pharmaceuticals, Inc., a Delaware corporation (“Tarsus”), and Alkeus Pharmaceutical...

Received 201 shares by exercise or conversion · Sold 12,500 shares ($980K)

Received 302 shares by exercise or conversion

Received 201 shares by exercise or conversion

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underl...

Sold 13,953 shares ($1.22M)

Sold 10,000 shares ($906K)

Sold 4,564 shares ($388K)

Sold 10,000 shares ($801K)

Sold 4,601 shares ($340K) · Sold 6,977 shares ($558K)